Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer
Status:
Completed
Trial end date:
2011-12-21
Target enrollment:
Participant gender:
Summary
The purpose of this research project is to study the effect of a research (investigational)
drug, MK-0752 combined with either tamoxifen or letrozole on breast cancer cells.
Tamoxifen and letrozole are standard hormone treatments used to treat breast cancers that are
positive for the estrogen receptor. However, over time the breast cancer cells can become
resistant to tamoxifen and letrozole. MK-0752 is in a class of drugs called gamma secretase
inhibitors. Gamma secretase inhibitors may play a role in reversing the resistance to drugs
such as tamoxifen and letrozole.